Pressmeddelande

BioStock: Medivir's CEO comments on the latest developments

Cision Publicerad: 19 Feb 08:52

As Medivir reports its fourth quarter, the company’s focus is on the further improved clinical efficacy of fostrox in combination with Lenvima in liver cancer. After recently having strengthened the cash position by more than 140 million SEK, now the aim is to accelerate the initiation of a pivotal phase IIb study and apply for accelerated approval from the FDA. BioStock reached out to CEO Jens Lindberg for a comment.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2024/02/medivirs-ceo-comments-on-the-latest-developments/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Medivir

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!